A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine

KORNUTA, CLAUDIA; SORIA, IVANA; GALARZA, ROXANA; QUATTROCCHI, VALERIA; BIDART, JUAN; GNAZZO, VICTORIA; MONGINI, CLAUDIA; LUPI, GIULIANA; ZAMORANO, PATRICIA; BIDART, JUAN; GNAZZO, VICTORIA; MONGINI, CLAUDIA; LUPI, GIULIANA; ZAMORANO, PATRICIA; GAMMELLA, MARIELA; LANGELLOTTI, CECILIA; CALVINHO, LUIS; MARCIPAR, IVAN; GAMMELLA, MARIELA; LANGELLOTTI, CECILIA; CALVINHO, LUIS; MARCIPAR, IVAN; KORNUTA, CLAUDIA; SORIA, IVANA; GALARZA, ROXANA; QUATTROCCHI, VALERIA

Frontiers in Veterinary Science

Frontiers Media S.A.

Año: 2020 vol. 7

Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important economy losses. Vaccines with new low-cost adjuvants that stimulate protective immune responses are needed and can be assayed in a mouse model to predict their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine, cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus, in the present work, we studied the effects on the magnitude and type of immunity elicited in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV) formulated with ISPA. It was demonstrated that iFMDV?ISPA induced protection in mice against challenge and elicited a specific antibody response in sera, characterized by a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an expected percentage of protection (EPP) higher than 80%. EPP calculates the probability that livestock would be protected against a 10,000 bovine infectious doses challenge after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine, iFMDV?ISPA elicited an increased specific T-cell response against the virus, including higher interferon gamma (IFNγ)+/CD8+ lymphocyte production in cattle. In this work, we report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is capable of inducing protection against challenge in a murine model and of improving the specific immune responses against the virus in cattle.